2021 Targeted Therapies Patient Forum
CancerGRACE
Targeted Therapies in Oligo-Metastatic NSCLC
FEATURING
Ticiana Leal
- 35 views
- June 3, 2022
CancerGRACE
Genotype Directed Therapies: Their Role in Earlier Stage NSCLC
FEATURING
Zofia Piotrowska
- 4 views
- June 3, 2022
GRACE
The Role of Chemotherapy in Driver Positive NSCLC
FEATURING
Jared Weiss
- 37 views
- June 3, 2022
- 1
CancerGRACE
Is There a Role for Chemo + IO in NSCLC With EGFR Mutations and When to Use It?
- 83 views
- June 3, 2022
- 1
GRACE
Is There a Role for Single Agent Immunotherapy Ever in Driver Mutation Positive NSCLC Patients?
- 80 views
- June 3, 2022
- 1
GRACE
Targeted Therapy for Rare NSCLC Drivers: NTRK, RET, and HER2
FEATURING
Millie Das
- 139 views
- April 20, 2022
- 1
GRACE
Tissue Genotyping: Challenges and Best Practices - Optimal NGS Platforms and How to Interpret
FEATURING
Jared Weiss
- 785 views
- April 20, 2022
- 8
GRACE
Current Standards and Novel Therapies for Sensitizing Mutations in EGFRm NSCLC
FEATURING
Jack West
- 49 views
- April 20, 2022
CancerGRACE
Common Mutations Changing to Different Drivers: Should NSCLC Be Biopsied for New Mutations at Progression on TKIs?
FEATURING
Jack West,
Justin Gainor
- 103 views
- April 20, 2022
- 1
GRACE
ALK Therapies in NSCLC: Which One Comes First and How Do We Sequence
FEATURING
Chul Kim
- 116 views
- April 20, 2022
GRACE
ROS1 Therapies in NSCLC: Current and Emerging Treatment Options
FEATURING
Jessica Lin
- 219 views
- April 20, 2022
CancerGRACE
NSCLC Q&A: After CRT, What Is Recommended for 2L Treatment and Timing in Stage 3 ROS1+ Lung Cancer?
FEATURING
Jessica Lin,
Chul Kim
- 21 views
- April 20, 2022
GRACE
KRAS Directed Therapies in NSCLC: A New Horizon
FEATURING
Lyudmila Bazhenova
- 240 views
- April 20, 2022
- 1
GRACE
Liquid Biopsies in NSCLC: Current Applications
FEATURING
Jeffrey Thompson
- 166 views
- April 19, 2022